CNTY 104
Alternative Names: CNTY-104Latest Information Update: 24 Mar 2022
At a glance
- Originator Century Therapeutics
- Class Antineoplastics; CAR-NK cell therapies; CAR-T cell therapies; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Acute myeloid leukaemia
Most Recent Events
- 10 Jan 2022 Century Therapeutics and Bristol Myers Squibb enters into a collaboration agreement to develop CNTY 104
- 31 Aug 2021 Century Therapeutics announces intention to submit IND application to regulatory bodies for Acute myeloid leukaemia in the first half of 2024 (Century Therapeutics pipeline, August 2021)
- 31 Aug 2021 Century Therapeutics pipeline, August 2021: NP created; intro, dev table, FET, planned trial HE and deal added, Thes drug term addition request sent; please update profile when more info available